(ATRC) and the Role of Price-Sensitive Allocations
Atricure Inc. (NASDAQ: ATRC) shows strong near-term sentiment with neutral mid and long-term outlooks, featuring a mid-channel oscillation pattern. AI models suggest specific institutional trading strategies, including long, breakout, and short positions, with an exceptional 65.4:1 risk-reward setup targeting a 19.5% gain versus 0.3% risk. The analysis provides multi-timeframe signal insights, including support and resistance levels for various holding periods.
AtriCure director Karen Prange sells $85,950 in company stock
AtriCure director Karen Prange sold 3,000 shares of the company's common stock for $85,950 on May 20, 2026, reducing her direct ownership to 26,373 shares. This insider sale comes as AtriCure's stock is down 27% year-to-date, despite the company reporting strong Q1 2026 financial results with increased revenue and reiterated guidance. Needham maintained a Buy rating on ATRC with a $45.00 price target, reflecting confidence in its strategic direction.
AtriCure director Karen Prange sells $85,950 in company stock
AtriCure director Karen Prange sold 3,000 shares of company stock for $85,950 on May 20, 2026, lowering her direct holdings to 26,373 shares. This sale comes as AtriCure's stock is down 27% year-to-date, despite recent positive financial results for Q1 2026 with strong revenue growth and a reiterated "Buy" rating from Needham. The company maintained revenue and adjusted EBITDA guidance for 2026.
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC)
Karen Prange, a Director at AtriCure Inc (ATRC), sold 3,000 shares of the company on May 20, 2026, reducing her holdings to 26,373 shares. This transaction follows a pattern of 12 insider sells and no insider buys for AtriCure over the past year. The stock is currently priced at $28.65, giving it a GuruFocus Value of $39.37, indicating it is modestly undervalued with a price-to-GF-Value ratio of 0.73.
AtriCure (ATRC) director Prange sells 3,000 shares, keeps 26,373
AtriCure director Karen Prange sold 3,000 shares of common stock on May 20, 2026, at a weighted average price of $28.65 per share. Following this open-market transaction, Prange retains a direct holding of 26,373 shares of AtriCure common stock. This sale represents a modest disposition from a substantial equity stake, with the transaction executed through multiple trades.
Director Nachman Shlomo receives 6,144 AtriCure (ATRC) restricted shares
AtriCure director Nachman Shlomo was granted 6,144 restricted shares of AtriCure, Inc. common stock at no cash cost under the company’s 2023 Stock Incentive Plan. These shares will fully vest one year from the grant date. Following this transaction, Shlomo directly owns 24,655 shares of AtriCure common stock.
AtriCure (ATRC) director Regina Groves receives 6,144-share restricted stock grant
AtriCure director Regina E. Groves was granted 6,144 shares of common stock as a Restricted Stock Award under the company's 2023 Stock Incentive Plan. These shares, with a grant price of $0.00, will vest on the one-year anniversary of the grant date. Following this transaction, Ms. Groves directly holds 39,859 shares of AtriCure common stock.
AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant
AtriCure (ATRC) director Sven Wehrwein received a restricted stock grant of 6,144 shares as equity compensation, with a grant price of $0.00 per share. These shares, awarded under the AtriCure, Inc. 2023 Stock Incentive Plan, will vest on the one-year anniversary of the grant date. Following this transaction, Wehrwein directly holds a total of 40,518 shares of AtriCure common stock.
Director Karen Prange granted 6,144 AtriCure (ATRC) shares
AtriCure director Karen Prange was granted 6,144 restricted shares of common stock as equity compensation under the company's 2023 Stock Incentive Plan. These shares were acquired at no cash cost and will vest on the one-year anniversary of the grant date. Following this transaction, Prange directly holds 29,373 AtriCure common shares.
AtriCure (ATRC) director Deborah Telman awarded 6,144 restricted shares
AtriCure director Deborah Telman was granted 6,144 restricted shares of common stock under the company's 2023 Stock Incentive Plan. These shares, which were awarded at a price of $0.00, will vest on the one-year anniversary of the grant date. Following this transaction, Telman now directly holds 28,328 shares of AtriCure common stock.
AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award
AtriCure, Inc. director Maggie Yuen was granted 6,144 shares of common stock as restricted stock on May 18, 2026, under the company's 2023 Stock Incentive Plan. The shares, awarded at $0.00 per share, will vest on the one-year anniversary of the grant date. Following this award, Yuen directly holds 17,515 shares of AtriCure common stock.
Director at AtriCure (ATRC) receives 6,144-share restricted stock grant
AtriCure director Robert S. White received a grant of 6,144 shares of common stock as a Restricted Stock Award under the company's 2023 Stock Incentive Plan. This award has no purchase price and will vest completely on the one-year anniversary of the grant date. Following this grant, White directly holds a total of 128,318 shares of AtriCure common stock, representing routine equity-based compensation.
[144] AtriCure, Inc. SEC Filing
This SEC filing (Form 144) for AtriCure, Inc. (ATRC) concerns a proposed sale of 3,000 shares of common stock with an aggregate market value of $86,400. The securities were acquired on May 13, 2025, as a stock award and are to be sold on NASDAQ. The filing indicates a neutral impact and sentiment.
AtriCure Shareholders Approve Expanded Equity and Governance Plans
AtriCure (ATRC) shareholders have approved several key proposals, including expanding its 2023 Stock Incentive Plan to 6 million shares and electing nine directors. They also ratified Deloitte & Touche as auditor and backed executive pay, indicating strong support for the company's governance. TipRanks' AI Analyst, Spark, rates ATRC as Neutral due to strengthening fundamentals offset by weak technicals and unfavorable valuation.
AtriCure (ATRC) stockholders back equity plan share increases and director slate
AtriCure, Inc. stockholders approved all management proposals at their 2026 Annual Meeting, including increasing the share pools for the 2023 Stock Incentive Plan by 1,500,000 shares and the 2018 Employee Stock Purchase Plan by 750,000 shares. They also re-elected all nine directors for one-year terms, ratified Deloitte & Touche LLP as the independent auditor for 2026, and supported executive compensation through an advisory say-on-pay vote. These approvals aim to enhance employee incentives, maintain board continuity, and confirm ongoing financial oversight.
AtriCure conference: New devices, EnCompass drive 2026 growth outlook
This article mentions that AtriCure's growth outlook for 2026 is being driven by new devices and its EnCompass product. No further details are available in the provided content.
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC)
Vinayak Doraiswamy, Chief Scientific Officer at AtriCure Inc (ATRC), sold 5,000 shares of the company on May 15, 2026, reducing his total ownership to 91,875 shares. This sale is part of a trend for Doraiswamy, who has sold 15,000 shares over the past year with no purchases. AtriCure Inc's stock was trading at $28.13 at the time of the sale, considered modestly undervalued with a price-to-GF-Value ratio of 0.72.
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $28.13
AtriCure, Inc. (ATRC) Chief Scientific Officer Doraiswamy Vinayak sold 5,000 shares of common stock at $28.13 per share in an open-market transaction on May 15, 2026. Following this sale, Vinayak directly holds 91,875 AtriCure common shares. The transaction, reported on a Form 4 SEC filing, represents a total value of $140,650 and indicates a "moderate" filing impact and "negative" sentiment according to Rhea-AI.
ATRC (NASDAQ: ATRC) Form 144 shows 5,000-share sale and planned award disposals
A recently filed Form 144 for AtriCure, Inc. (ATRC) discloses a sale of 5,000 shares by Vinayak Doraiswamy on March 12, 2026, for $149,151.50. The filing also outlines planned dispositions of various performance shares and restricted stock awards granted on March 1, 2024, in several specific lots. This administrative filing provides transparency regarding proposed and recent insider transactions.
Wellington Management holds 3,382,555 ATRC shares (6.79%) — institutional stake
Wellington Management Group LLP and related entities have filed an amendment revealing a beneficial ownership of 3,382,555 shares, totaling 6.79% of AtriCure's common stock. These shares are held on behalf of Wellington's investment adviser clients. The filing clarifies that voting and dispositive powers are shared among the Wellington entities and emphasizes the passive nature of this institutional stake.
AtriCure Inc (ATRC) Shares Surge 5.8% -- What GF Score of 79 Tel
AtriCure Inc (ATRC) shares surged 5.8% to $28.14, putting it within a 52-week range of $25.52 to $43.18. Despite the surge, the stock is considered "Modestly Undervalued" by GuruFocus' GF Value™ with a fair value estimate of $39.27, suggesting a potential upside of 28.3%. The company's GF Score™ of 79/100 indicates above-average long-term performance potential, driven by strong growth but tempered by lower profitability and recent insider selling.
AtriCure Inc (ATRC) Shares Surge 5.8% -- What GF Score of 79 Tells Investors
Shares of AtriCure Inc (ATRC) rose 5.8% to $28.14 on May 14, 2026. According to GuruFocus' GF Value, the stock is considered "Modestly Undervalued" with a potential upside of 28.3% from its fair value estimate of $39.27. However, insider selling amounting to $0.1 million in the last three months signals caution despite a strong GF Score of 79/100, driven by robust growth potential but tempered by profitability concerns.
AtriCure, Inc. - Common Stock (NQ: ATRC)
This page provides recent news and financial updates for AtriCure, Inc. (Nasdaq: ATRC), including analyst reviews, conference participations, and quarterly financial results. It features a continually updated list of press releases and research, highlighting product launches, regulatory approvals, and earnings reports. The latest stock quote shows ATRC at 28.15, unchanged as of May 14, 2026, 4:00 PM EDT.
AtriCure stock (US04963C1099): Q1 revenue jumps 14% to $141M amid return to profit
AtriCure (ATRC) reported strong first-quarter 2026 results, with revenue increasing 14% to $141.25 million and a swing to net income of $0.108 million. Despite these improved financials, the stock experienced a 5.1% drop following the announcement. The company specializes in devices for cardiac tissue ablation and pain management, and forecasts 12.8% annual revenue growth to $717.8 million by 2028.
AtriCure (ATRC) Is Down 5.1% After Q1 Return To Profitability And Higher Revenue Guidance – What's Changed
AtriCure (ATRC) reported a return to profitability in Q1 2026 with revenues of US$141.25 million, up from US$123.62 million year-over-year, and issued higher revenue guidance for 2026. The company's growth is driven by recent product launches and increased adoption of its platforms. Despite these positive results and an improving investment narrative, the stock was down 5.1%, with analysts noting potential challenges from intensifying competition in pulsed field ablation.
AtriCure, Inc. $ATRC Shares Purchased by Vanguard Group Inc.
Vanguard Group Inc. increased its stake in AtriCure, Inc. (NASDAQ:ATRC) by 1.3% in the fourth quarter, purchasing an additional 62,861 shares to own 4.9 million shares, representing 9.86% of the company. AtriCure recently reported breakeven EPS and revenue of $141.25 million, exceeding analyst expectations, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $48.71.
Responsive Playbooks and the ATRC Inflection
This article provides an analysis of Atricure Inc. (NASDAQ: ATRC), highlighting weak near and mid-term sentiment and a neutral long-term outlook, with a breakdown currently underway. It offers three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing support and resistance levels. The report suggests elevated downside risk due to the absence of additional long-term support signals.
Number of shareholders of AtriCure, Inc. – NASDAQ:ATRC
The article focuses on the number of shareholders for AtriCure, Inc. (NASDAQ: ATRC). It is presented on a financial data platform, showing the company's stock information and financial overview. The main content regarding shareholder numbers is listed under "Period," "Value," "Change," and "Change %" but the actual data is not populated in the provided text.
Number of shareholders of AtriCure, Inc. – DUS:A5I
This article from TradingView provides financial information for AtriCure, Inc. (DUS:A5I), specifically focusing on the number of shareholders. It is a data-oriented page that presents the period, value, and change in share ownership for the company.
Assessing AtriCure (ATRC) Valuation After A Prolonged Share Price Pullback
AtriCure (ATRC) has experienced a significant share price decline, making its valuation a current point of interest for investors. While a popular narrative suggests the stock is undervalued at $52.78 per share due to future clinical and product milestones, a discounted cash flow model by Simply Wall St indicates it might be overvalued at its current price of $27.80. Investors are urged to consider both earnings potential and cash flow analysis to make informed decisions.
F m Investments LLC Purchases Shares of 72,588 AtriCure, Inc. $ATRC
F m Investments LLC has acquired a new stake in AtriCure, Inc. (NASDAQ:ATRC), purchasing 72,588 shares valued at approximately $2.87 million, representing about 0.15% of the company. Institutional ownership of AtriCure remains high at 99.11%, with several firms increasing their positions. The company recently reported better-than-expected quarterly results, achieving breakeven EPS on revenue of $141.25 million, up 14.3% year-over-year.
AtriCure Inc stock hits 52-week low at 26.62 USD By Investing.com
AtriCure Inc.'s stock recently dropped to a new 52-week low of $26.62, representing a 13% decline over the past year and nearly 30% year-to-date in 2026. Despite this downturn and current market challenges, InvestingPro analysis suggests the stock may be undervalued. This comes after the company reported strong Q1 2026 revenue exceeding expectations and improved profitability, leading Needham to reiterate a "Buy" rating with a $45 price target.
AtriCure (ATRC) Q1 Breakeven EPS Tests Bullish Profitability Narrative
AtriCure (ATRC) reported Q1 2026 revenue of US$141.2 million and breakeven basic EPS, contrasting with a US$4.6 million net loss over the trailing 12 months. The company's ongoing investment for growth is highlighted by expected revenue growth of 11% and earnings growth of 47.55% per year, although profitability is not yet established. This financial profile creates tension between bullish growth narratives and bearish concerns over persistent losses and valuation.
AtriCure Inc stock hits 52-week low at 26.62 USD
AtriCure Inc.'s stock has fallen to a new 52-week low of $26.62, representing a 30% year-to-date decline and a 13% drop over the past year. Despite this, InvestingPro analysis suggests the stock may be undervalued. The company recently reported strong Q1 2026 results with revenue surpassing expectations and Needham reiterating a Buy rating with a $45 price target.
AtriCure (ATRC) Q1 Breakeven EPS Tests Bullish Profitability Narrative
AtriCure (ATRC) reported Q1 2026 revenue of US$141.2 million with breakeven basic EPS, showing improvement from previous losses despite still having a net loss of US$4.6 million over the trailing 12 months. The article discusses the tension between growing revenue and ongoing losses, highlighting analysts' expectations for future growth and profitability versus current trailing figures. It also examines the stock's valuation, comparing its P/S ratio to industry averages and its DCF fair value against analyst targets, ultimately presenting both bullish and bearish perspectives on AtriCure's financial trajectory.
AtriCure : Investor Presentation Q1 2026 vF
AtriCure presented its Q1 2026 investor presentation, highlighting its vision to be a global leader in treating Afib and post-operative pain. The company detailed its market opportunities, which are projected to reach over $10 billion by 2030, and its pipeline of innovative products and clinical trials. AtriCure also reported strong financial results for Q1 2026, with worldwide revenue of $141.2 million and positive net income, while maintaining its 2026 guidance and outlining aspirational goals for 2028 and 2030.
AtriCure Q1 Loss Narrows, Revenue Increases; 2026 Guidance Maintained
AtriCure (NASDAQ: ATRC) reported a narrower loss and increased revenue for the first quarter. The company posted a GAAP diluted EPS loss of $0.46, an improvement from $0.62 in the prior year, and non-GAAP diluted EPS loss of $0.21. Revenue rose 12.8% to $119.5 million, with growth across all reporting segments, and the company reaffirmed its financial guidance for 2026.
AtriCure, Inc. (NASDAQ:ATRC) Q1 2026 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC) reported strong Q1 2026 results with worldwide revenue of $140 million, a 14% year-over-year growth, driven by key product adoption and its U.S. business. The company also announced exceptional progress in its BoxX-NoAF clinical trial, expecting to complete enrollment nearly a year ahead of schedule. Despite some international headwinds and challenges in the minimally invasive ablation franchise, AtriCure reiterated its full-year 2026 revenue guidance of $600 million to $610 million and adjusted EBITDA of $80 million to $82 million, emphasizing its commitment to innovation and profitability.
AtriCure, Inc. 1Q 2026: Revenue $141.25M, EPS $0— 10-Q Summary
AtriCure, Inc. reported strong first-quarter 2026 results with revenue increasing by 14.3% to $141.25 million and a net income of $108K, a significant improvement from a loss of $6.75 million in the prior-year quarter. Diluted EPS was $0, up from ($0.14) in Q1 2025. The company's growth was driven by strong performance in appendage products, pain management, and open ablation, alongside successful new product introductions.
Needham reiterates Buy on AtriCure stock after Q1 beat
Needham has reaffirmed its Buy rating and $45.00 price target for AtriCure Inc. (NASDAQ:ATRC) after the company surpassed Q1 consensus expectations for revenue, EBITDA, and EPS. Despite maintaining 2026 revenue and adjusted EBITDA guidance, EPS guidance was lowered, though Needham believes the overall guidance is conservative with potential for upside. AtriCure also improved revenue growth and achieved positive net income for the second consecutive quarter, with BoxX-NoAF enrollment expected to conclude a year early.
AtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. announced strong first-quarter 2026 financial results, with worldwide revenue increasing by 14.3% year-over-year to $141.2 million, and U.S. revenue growing by 14.9%. The company also reported improved profitability with a net income of $0.1 million and adjusted EBITDA of $17.1 million, driven by increased adoption of innovative products. AtriCure maintained its full-year 2026 financial guidance, projecting revenue between $600 million and $610 million and adjusted EBITDA of $80 million to $82 million.
Transcript : AtriCure, Inc., Q1 2026 Earnings Call, May 05, 2026
This article is a transcript of AtriCure, Inc.'s First Quarter 2026 Earnings Conference Call held on May 05, 2026. The company reported Q1 revenue of $141.2 million, surpassing the FactSet estimate of $139.7 million, and adjusted EPS of $0.00, compared to an estimated $-0.06. The full transcript content is reserved for subscribers.
AtriCure Q1 2026 Earnings Call Transcript
AtriCure reported strong Q1 2026 results with worldwide revenue of $141.2 million, a 14.3% year-over-year growth, driven by new product adoption and pain management devices. The company's Box NOAF clinical trial is significantly ahead of schedule, with enrollment expected to be completed by year-end, almost a year earlier than planned. AtriCure reiterated its 2026 revenue guidance of $600 million to $610 million and adjusted EBITDA guidance of $80 million to $82 million.
Earnings Flash (ATRC) AtriCure, Inc. Reports Q1 Revenue $141.2M, vs. FactSet Est of $139.7M
AtriCure, Inc. (ATRC) announced Q1 revenue of $141.2 million, surpassing the FactSet estimate of $139.7 million. Additionally, the company reported Q1 adjusted EPS of $0.00 per share, outperforming FactSet's estimate of $-0.06. This positive financial performance indicates stronger-than-anticipated results for the medical equipment company.
AtriCure (NASDAQ: ATRC) Q1 2026 revenue jumps 14% to $141M
AtriCure reported strong first-quarter 2026 financial results, with revenue increasing 14.3% year-over-year to $141.2 million, driven by robust U.S. sales of key medical devices. The company returned to profitability with a net income of $0.1 million and significantly improved its adjusted EBITDA to $17.1 million, nearly doubling from the previous year. AtriCure also issued optimistic full-year 2026 guidance, projecting revenues between $600 million and $610 million and continued positive cash flow.
AtriCure earnings up next: Profitability goal faces first test
AtriCure Inc. is reporting its first-quarter results, with analysts expecting a loss of 6 cents per share on revenue of $139.5 million. Investors will be focused on whether the company reiterates its full-year profitability guidance for 2026, especially as it faces increasing competition in its key AtriClip market. The report will also shed light on the progress of its new product platforms, which are crucial for offsetting weaknesses in other business segments.
AtriCure stock hits 52-week low at $27.04 By Investing.com
AtriCure's stock has dropped to a new 52-week low of $27.04, reflecting a significant year-to-date decline of 28% and 17.8% over the past year. Despite this downturn, analysts believe the stock is undervalued, with five analysts recently revising earnings upward and predicting profitability for the current year. The company's next earnings report, due in six days, is keenly awaited for further signals.
Understanding the Setup: (ATRC) and Scalable Risk
This article from Stock Traders Daily discusses Atricure Inc. (NASDAQ: ATRC), identifying a neutral sentiment across all time horizons and suggesting a wait-and-see approach due to elevated downside risk. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights the predictive AI's ability to offer real-time signals, risk management, and multi-timeframe analysis for institutional trading strategies.
AtriCure stock hits 52-week low at $27.04 By Investing.com
AtriCure Inc.'s stock recently hit a 52-week low of $27.04, reflecting a significant year-to-date and annual decline despite positive fourth-quarter 2025 earnings which surpassed analyst expectations. While some analysts maintain a "Buy" or "Market Outperform" rating with adjusted price targets, noting the stock is undervalued and predicting future profitability, others have downgraded their ratings due to competitive concerns. Investors are now closely watching the upcoming May 5th earnings report for further signals, particularly the potential for the company to turn profitable this year.
[SCHEDULE 13G] AtriCure, Inc. Passive Investment Disclosure (>5%)
Vanguard Capital Management has filed a Schedule 13G indicating a passive investment in AtriCure Inc., beneficially owning 2,532,965 shares of common stock, which represents 5.08% of the class. The filing details that Vanguard Capital Management has sole voting power over 377,201 shares and sole dispositive power over all 2,532,965 shares. This disclosure reflects a passive stake, with future filings required if Vanguard's intent or voting role changes.
